NEW
Stock Screener with Intrinsic Value
Summit Therapeutics Inc. (SMMT)
Last Price$19.04.6%
Market Cap$13.8B
LTM Free Cash Flow
($112.9M)
Reverse DCF (Implied FCF growth)
(100.0%)
3Y Free Cash Flow CAGR
16.4%
LTM Revenue
($235.0K)
Reverse DCF (Implied Revenue growth)
(100.0%)
at normalized FCF margin 44,750.7%
3Y Revenue CAGR
N/A
SMMT Reverse DCF Model
Crunching data... Almost there!
Best stock ideas on the market right now
With Value Sense, you can find undervalued stocks list with intrinsic value. Discover more stock market investment ideas.
SMMT Free Cash Flow
Crunching data... Almost there!
SMMT Growth
Crunching data... Almost there!
SMMT vs Peer Set: Reverse DCF comparison
Crunching data... Almost there!
Explore more intrinsic value tools hub for SMMT
DCF value calculator
Peter Lynch Fair Value
Discount rate
Relative Value
Earnings growth model
Peter Lynch charts
Margin of safety
Intrinsic Value
Earnings Power Value
Ben Graham Fair Value
Loved by
investors
worldwide
investors
worldwide
10K+
Investors
use our platform
#1
Top value investing hub
with all necessary tools
1K+
Experienced investors
in our community
4.9
Average rating across
all rating platforms
FAQ
What is Summit Therapeutics Inc. Reverse DCF (discounted cash flow) valuation?
As of Sep 30, 2024, Summit Therapeutics Inc.'s Reverse Discounted Cash Flow (DCF) valuation estimates its Free Cash Flow growth at (100.0%).
What is Summit Therapeutics Inc. WACC?
As of Sep 30, 2024, Summit Therapeutics Inc.'s Weighted Average Cost of Capital (WACC) is approximately 6.9%.
What is Summit Therapeutics Inc. Free Cash Flow?
As of Sep 30, 2024, Summit Therapeutics Inc.'s Free Cash Flow is ($112.9M).